Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Lindsay Rein, Nathan Boggs, Prithviraj Bose, Brian Modena, Vito Sabato, Karin Hartmann, Cem Akin, Tracy George, Cecilia Arana Yi, Hanneke Oude Elberink, Deepti Radia, Andreas Reiter, Miguel Piris-Villaespesa, Ingunn Dybedal, Jens Panse, Stephen Oh, Pankit Vachhani, Anthony Hunter, Mariana Castells, Cristina Bulai Livideanu, Paul van Daele, Arnold Kirshenbaum, Ivan Alvarez-Twose, Jennifer Vaughn, Minakshi Taparia, Sonia Cerquozzi, Andrzej Mital, Marek Hus, ALESSANDRA ROMANO, John Fahrenholz, Frederick Lansigan, Cristina Papayannidis, Helena Pomares, Michela Rondoni, Celalettin Ustun, Richard Herrscher, Michael Manning, Stéphane Barete, Mar Guilarte, Candido Rivera, Jonathan Bernstein, Peter Vadas, Chiara Elena, Derek McCulloch, Nina Orfali, Clodagh Keohane, Francesco Mannelli, Philippe Schafhausen, Amanda Pilla, Jenna Zhang, Lei Sun, Nisha Shah, Hina Jolin, Rachael Easton, Jessica Sachs, Frank Siebenhaar, Daniel Deangelo

Blood (2025) 146 (Supplement 1): 80.

https://doi.org/10.1182/blood-2025-80

Published: 2025

Journal Articles

Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

Daniel J. DeAngelo, Vinod A. Pullarkat, Miguel Piris-Villaespesa, Tracy I. George, Jay L. Patel, Celalettin Ustun, Prithviraj Bose, Mark L Heaney, Jessica Sachs, Lei Sun, Amanda Pilla, Benjamin Exter, Hina A. Jolin, Tsewang Tashi

Blood (2022) 140 (Supplement 1): 1512–1513.

https://doi.org/10.1182/blood-2022-156311

Published: 2022

Journal Articles

Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Cem Akin, Frank Siebenhaar, Michael W. Deininger, Daniel J. DeAngelo, Tracy I. George, Mariana Castells, Matthew Giannetti, Jason Gotlib, Jessica Sachs, Amanda Pilla, Hina A. Jolin, Prithviraj Bose

Blood (2022) 140 (Supplement 1): 6838–6839.

https://doi.org/10.1182/blood-2022-156326

Published: 2022

Journal Articles

Preclinical Data with KIT D816V Inhibitor Bezuclastinib (CGT9486) Demonstrates High Selectivity and Minimal Brain Penetrance

Anna Guarnieri, Mark Chicarelli, Louann Cable, Karyn Bouhana, Francis Sullivan, Howard Ball, Jessica Sachs, Shannon Winski, John Robinson

Blood (2021) 138 (Supplement 1): 4595.

https://doi.org/10.1182/blood-2021-152770

Published: 2021

Journal Articles

A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM)

Jason Gotlib, Tracy I. George, Michael W. Deininger, Tsewang Tashi, Vinod A. Pullarkat, Prithviraj Bose, Francis Payumo, Amanda Pilla, Hina Jolin, Jessica Sachs, Daniel J. DeAngelo

Blood (2021) 138 (Supplement 1): 3636.

https://doi.org/10.1182/blood-2021-145928

Published: 2021

Journal Articles

A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Frank Siebenhaar, Jason Gotlib, Michael W. Deininger, Daniel J. DeAngelo, Francis Payumo, George Mensing, Hina Jolin, Jessica Sachs, Tracy I. George

Blood (2021) 138 (Supplement 1): 3642.

https://doi.org/10.1182/blood-2021-147072

Published: 2021

Journal Articles

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

Ian W. Flinn, MD PhD, Jason R. Westin, MD, Jonathon B. Cohen, MDMS, Luke P. Akard, MD, Samantha Jaglowski, MDMPH, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Veronika Bachanova, MD PhD

Blood (2019) 134 (Supplement_1): 1587.

https://doi.org/10.1182/blood-2019-125995

Published: 2019

Journal Articles

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Javier Munoz, MD, Samantha Jaglowski, MDMPH, Matthew S. McKinney, MD, Iris Isufi, MD, Patrick J. Stiff, MD, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Luke P. Akard, MD

Blood (2019) 134 (Supplement_1): 244.

https://doi.org/10.1182/blood-2019-123810

Published: 2019

Journal Articles

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Don M. Benson, Jr., MD PhD, Houston Holmes, MD, Parameswaran Hari, MBBS, MD, Jessica Sachs, MD, Ben Exter, Ann Ranger, PhD, Tooba Cheema, PhD, Iga Sienczylo, BS, Megan M. O'Meara, MD, Django Sussman, PhD, Luke P. Akard, MD

Blood (2018) 132 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2018-99-111729

Published: 2018

Journal Articles

Adaptability of Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T Cells in Combination with Daratumumab over CAR-Based Approaches

Taylor Hickman, BS, Adrianna Graziano, Katie O'Callaghan, PhD, Ryan Boomer, BA, Eugene Choi, MS, Allison Nelson, BS, Greg Motz, PhD, Jessica Sachs, MD, Birgit Schultes, PhD, Seth Ettenberg, PhD, Tooba Cheema, PhD

Blood (2017) 130 (Supplement 1): 3189.

https://doi.org/10.1182/blood.V130.Suppl_1.3189.3189

Published: 2017

Journal Articles

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study

Blood (2017) 130 (Supplement 1): 6.

https://doi.org/10.1182/blood.V130.Suppl_1.6.6

Published: 2017

Journal Articles

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Franco Locatelli, MD, Kathleen A Neville, MD, MS, Angelo Rosolen, MD, Judith Landman-Parker, MD, Nathalie Aladjidi, MD, Auke Beishuizen, MD, Stephen Daw, BSc Hons, MBChB, MRCP, Lia Gore, MD, Anna R.K. Franklin, MD, Adedigbo Fasanmade, PhD, Jingyuan Wang, PhD, Jessica Sachs, MD, Christine Mauz-Koerholz, MD

Blood (2013) 122 (21): 4378.

https://doi.org/10.1182/blood.V122.21.4378.4378

Published: 2013

Journal Articles

Lymphopenia Promotes the Development of Graft-Versus-Host Disease upon Donor Leukocyte Infusion.

Jessica Sachs, MD, Megan Sykes, MD

Blood (2007) 110 (11): 2185.

https://doi.org/10.1182/blood.V110.11.2185.2185

Published: 2007

Journal Articles

Host MHC class II + antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions

Ronjon Chakraverty, Hyeon-Seok Eom, Jessica Sachs, Jennifer Buchli, Pete Cotter, Richard Hsu, Guiling Zhao, Megan Sykes

Blood (2006) 108 (6): 2106–2113.

https://doi.org/10.1182/blood-2006-03-007427

Published: 2006

Includes: Supplemental data

Journal Articles

Requirement for CD4 Help for Optimal GVL Effects of Alloreactive T Cells Given to Established Mixed Chimeras but Not Freshly Irradiated Mice.

Hyeon-Seok Eom, MD, PhD, Ronjon Chakraverty, MD, PhD, Jessica Sachs, MD, Guiling Zhao, Megan Sykes, MD

Blood (2004) 104 (11): 3044.

https://doi.org/10.1182/blood.V104.11.3044.3044

Published: 2004

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Preclinical Data with KIT D816V Inhibitor Bezuclastinib (CGT9486) Demonstrates High Selectivity and Minimal Brain Penetrance

A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM)

A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Adaptability of Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T Cells in Combination with Daratumumab over CAR-Based Approaches

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Lymphopenia Promotes the Development of Graft-Versus-Host Disease upon Donor Leukocyte Infusion.

Host MHC class II + antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions

Requirement for CD4 Help for Optimal GVL Effects of Alloreactive T Cells Given to Established Mixed Chimeras but Not Freshly Irradiated Mice.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only